Ritlecitinib Hits Primary Goals in Phase 3 Vitiligo Studies

Ritlecitinib (Litfulo, Pfizer) is showing promise in nonsegmental vitiligo, according to positive top-line results from two Phase 3 trials.

The TRANQUILLO study included patients aged 12 years and up, while TRANQUILLO 2 enrolled adults only. Across the studies, both the 50mg and 100mg doses of ritlecitinib delivered significant, clinically meaningful improvements over placebo on co-primary endpoints for the facial and total body Vitiligo Area Scoring Index (VASI).

Based on these results, Pfizer intends to submit global regulatory filings for ritlecitinib as a potential new oral systemic therapy for nonsegmental vitiligo in adults.

Across both studies, significantly more patients treated with ritlecitinib achieved Facial VASI75 (≥75% improvement in F-VASI) and Total Body VASI50 (≥50% improvement in Total-VASI) from baseline at Week 52 compared with placebo.

In the US, the co-primary endpoints were the proportion of patients with F-VASI75 and the proportion of patients with T-VASI50 at Week 52. (In countries outside of the US, F-VASI75 at Week 52 was the primary endpoint and T-VASI50 at Week 52 was a key secondary endpoint.)

The safety profile of ritlecitinib in nonsegmental vitiligo was consistent with the established safety profile in alopecia areata. No new safety signals were observed in TRANQUILLO and TRANQUILLO 2. Overall, the proportion of patients with treatment emergent adverse events (TEAEs) was similar across all treatment groups.

“In these trials, LITFULO (ritlecitinib) demonstrated significant improvements in both facial and total body repigmentation, with the findings reinforcing the potential of LITFULO to help support a new treatment paradigm with systemic therapies for patients for whom disease burden warrants more than localized treatment alone,” says Iltefat Hamzavi, MD, Senior Staff Physician in the Department of Dermatology at Henry Ford Health and Hamzavi Dermatology Specialists, in Detroit, MI.

Additional results from TRANQUILLO and TRANQUILLO 2 will be presented at a future medical meeting.